HomeInvestors & MediaNews
- Preclinical data suggest that ‘Grabody-T’ enhances anti-cancer activity without severe liver toxicity
- Preclinical studies indicate ABL501 (PD-L1xLAG-3 BsAb) has potential to enhance antitumor efficacy and overcome the resistance to current immunotherapies
March 11, 2021 – ABL Bio, Inc., a South Korean
biotech developing bispecific antibody technology for immuno-oncology and
neurodegenerative diseases, today announced it will make two poster presentations
at the virtual American Association for Cancer Research(AACR) 2021 Annual
Meeting.
The presentations
will focus on the preclinical data of ‘Grabody-T,’ a 4-1BB engaging bispecific antibody platform
that has demonstrated anti-tumor efficacy,
while successfully eliminating 4-1BB related liver toxicity issues. ABL will also
present new data regarding ABL501, a bispecific antibody targeting PD-L1 and LAG-3
checkpoint pathways.
The details of the presentation
are as follows:
Title: A novel anti-CD137
antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor
T cell activity in a bispecific antibody format
Abstract Control Number:
1250
Session Type: E-Poster
Session
Session Title: Therapeutic
Antibodies, Including Engineered Antibodies
Permanent Abstract Number:
1850
Title: ABL501, PD-L1 X
LAG-3, a bispecific antibody promotes enhanced human T cell activation through targeting
simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1
Abstract Control Number:
2255
Session Type: E-Poster
Session
Session Title: Immune
Checkpoints
Permanent Abstract Number:
1633
About ABL Bio
ABL Bio, Inc. (KOSDAQ: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-I’ and ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B platform, which is designed to maximize blood-brain barrier(BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com